Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.

SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

KAIST researchers unveil a new microbial strain for efficient, eco-friendly lutein production.

Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.

The tool is designed to help with the application of mono-dose, dry eye eyedrop vials more easily and accurately.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.

MCO-010 is a gene-agnostic therapy for retinitis pigmentosa.

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach.

Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.